Abilita Bio has filed a notice of an exempt offering of securities to raise $7,500,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Abilita Bio is raising $7,500,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Mauro Mileni played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Abilita Bio
Abilita Bio was founded in June 2014 and is a biotechnology company focused on enabling discovery and development of drugs targeting membrane proteins, including G Protein Coupled Receptors (GPCRs) and ion channels. We have established collaborations, and seek to expand collaborative research agreements with global pharmaceutical and biotechnology companies. We are currently incubating in JLabs San Diego (a life science innovation center operated by Janssen Research & Development).
To learn more about Abilita Bio, visit http://abilitabio.com/
Contact:
Mauro Mileni, Chief Executive Officer
858-246-6778
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.